Q BioMed partners with Eversana on Strontium89

2018 12 11 00 02 7009 Atom Nuclear Lab 400

Biotech company Q BioMed has partnered with life sciences firm Eversana to support the commercialization of its Strontium89 (strontium-89 chloride injection) therapeutic radiopharmaceutical in the U.S.

Q BioMed will use Eversana's full product commercialization model, which integrates services for market access, agency services, clinical and commercial field teams, health economics, and outcomes research and compliance.

Strontium89 is currently available in the U.S. for metastatic cancer bone pain palliation.

Page 1 of 436
Next Page